Cardiovascular
Landmark Study Demonstrates Lower Rate of Inappropriate Shocks in Patients with Sorin Dual Chamber ICD Devices
May 11, 2013 10:00 am | by The Associated Press | News | CommentsDENVER--(BUSINESS WIRE)--May 11, 2013--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced findings from the landmark OPTION study 1 demonstrating that patients with Sorin dual-chamber implantable cardioverter...
Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring
May 10, 2013 4:06 pm | by The Associated Press | News | CommentsMINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a...
Nanostim Announces Preliminary Results from LEADLESS Study in Late-Breaking Clinical Trial at Heart Rhythm 2013
May 10, 2013 3:42 pm | by The Associated Press | News | CommentsSUNNYVALE, Calif.--(BUSINESS WIRE)--May 10, 2013--Nanostim, Inc., a privately-owned developer of miniaturized, leadless cardiac pacemakers (LCP), today announced preliminary results from its LEADLESS study during the late breaking clinical trial presentations at Heart Rhythm 2013, the Heart Rhythm...
Sorin Group Announces FDA Approval and U.S. Launch OF SMARTVIEW Remote Monitoring Solution for Patients with Implanted Cardiac Defibrillators
May 10, 2013 12:04 pm | by The Associated Press | News | CommentsDENVER--(BUSINESS WIRE)--May 10, 2013--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, today announced it received FDA approval for and is beginning the U.S. launch of the SMARTVIEW™ remote monitoring solution for...
Medtronic Issues Statement on iPad Interference Study
May 10, 2013 11:02 am | by Medtronic | News | CommentsMedtronic's current internal analysis and testing shows iPad technology presents no risk of electromagnetic interference with Medtronic implantable cardiac rhythm devices when used per manufacturer's instructions. However, as a precaution, patients implanted with a pacemaker or ICD are advised to follow Apple and Medtronic labeling recommendations and maintain a distance of six inches between the iPad and implanted device.
Operating Without Interrupting Warfarin Reduces Risk of Bleeding After Cardiac Device Surgery
May 10, 2013 10:21 am | by University of Ottawa Heart Institute | News | CommentsA new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care. The new findings were released today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.
Weaving Flexibility and Strength into Stent Design
May 9, 2013 3:05 pm | by Kasey Panetta, Managing Editor, ECN | Articles | CommentsThough traditional laser-cut stents made from nitinol are effective, the design trades flexibility for strength, which means the stents are at risk for fracture, crushing, and kinking. This is a particular issue when the stents are used with patients suffering from femoropopliteal or proximal popliteal artery disease.
St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013
May 9, 2013 1:55 pm | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has conducted a further independent analysis of data received from...
New Four-Year Data From Boston Scientific Demonstrated WATCHMAN Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial
May 9, 2013 12:02 pm | by The Associated Press | News | CommentsBoston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN@ Left Atrial Appendage (LAA) Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic...
First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ™ Pulmonary Vein Isolation System™ in the Treatment of Paroxysmal Atrial Fibrillation
May 9, 2013 9:49 am | by The Associated Press | News | CommentsDIAMOND BAR, Calif.--(BUSINESS WIRE)--May 9, 2013--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, today announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of...
Thoracic Endografts Used Successfully to Remove Tumors Invading the Aorta
May 8, 2013 10:43 am | by American Association for Thoracic Surgery | News | CommentsSome chest tumors may invade one of the great vessels of the body, the aorta. Surgical removal of these tumors is very challenging and necessitates the support of a heart-lung machine. Therefore, there is an increased risk of complication and death. In a small series of patients, placing a stent within the aorta facilitated the subsequent removal of tumor and eliminated the need for heart-lung bypass.
Heart Rhythm 2013 - ScottCare Launches Innovations in Universal Management of Cardiac Implantable Electronic Device (CIED) Data
May 8, 2013 9:00 am | by The Associated Press | News | CommentsCLEVELAND--(BUSINESS WIRE)--May 8, 2013--As a technology leader in devices and software for cardiology diagnosis, therapy and rehabilitation, ScottCare will unveil new advances in importing, monitoring and reviewing CIED data at this year’s Heart Rhythm Society’s Scientific Session, Heart Rhythm...
St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices
May 8, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy...
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States
May 8, 2013 7:00 am | by The Associated Press | News | CommentsSUNNYVALE, Calif--(BUSINESS WIRE)--May 8, 2013--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration (FDA) to initiate patient enrollment...
Demand for Hybrid Solutions to Spur European Interventional Radiology and Cardiology Markets, finds Frost & Sullivan
May 8, 2013 4:00 am | by PR Newswire | News | CommentsLONDON, May 8, 2013 /PRNewswire/ -- The European market for interventional radiology and cardiology is heading towards maturity, especially in Western Europe. Although the economic slowdown and fewer orders had a negative impact on revenues in 2012, it is expected that expanding...
A Living Patch for Damaged Hearts
May 7, 2013 10:10 am | by Duke University | News | CommentsDuke University biomedical engineers have grown three-dimensional human heart muscle that acts just like natural tissue. This advancement could be important in treating heart attack patients or in serving as a platform for testing new heart disease medicines.
FDA Approves BIOTRONIK’s Ilesto 7 ICD/CRT-D Series
May 7, 2013 10:02 am | by The Associated Press | News | CommentsLAKE OSWEGO, Ore.--(BUSINESS WIRE)--May 7, 2013--BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced that the Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator...
Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups For On-X® Prosthetic Heart Valve Anticoagulation Clinical Study
May 7, 2013 9:00 am | by The Associated Press | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--May 7, 2013--On-X ® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated with US FDA...
The Future of Energy-Based Surgical Systems
May 6, 2013 2:43 pm | by Steven Walsh, Ph.D., VP of R&D, and Nikolay Suslov, Ph.D., EVP and CTO, Plasma Surgical | Blogs | CommentsUnique energy-based surgical devices afford broad clinical use in the cutting, coagulation, and ablation of tissues using a high velocity jet of thermal plasma, and the PlasmaJet surgical system is one example of this medical device evolution. Plasma is formed when sufficient energy is added to remove outer electrons from a gas to form ions.
Medtronic Announces FDA Approval of New Portfolio Of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-Defibrillators
May 6, 2013 10:18 am | by Medtronic | News | CommentsMedtronic, Inc. has announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva® portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibrillators (ICD).
AATS Report: Prospective Randomized On-X Heart Valve Clinical Trial (PROACT) Provides Evidence of Reduced Complications
May 6, 2013 9:00 am | by The Associated Press | News | CommentsMINNEAPOLIS--(BUSINESS WIRE)--May 6, 2013--On-X ® Life Technologies, Inc. (On-X LTI) announced today that interim results for the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT) are being presented at the American Association for Thoracic Surgery Annual (AATS) meeting by John...
AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
May 6, 2013 9:00 am | by PR Newswire | News | CommentsBOSTON, May 6, 2013 /PRNewswire/ -- AG Mednet today announced a new core lab partnership with the Methodist DeBakey Heart & Vascular Center (MDHVC) echocardiography core laboratory at The Methodist Hospital in Houston. By selecting AG Mednet quality assurance and compliance...
Hansen Medical to Exhibit Magellan Robotic System at 8th Annual European Symposium of Vascular Biomaterials in France
May 6, 2013 8:03 am | by The Associated Press | News | CommentsHansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will be exhibiting its Magellan Robotic System at the 8th Annual European Symposium of Vascular Biomaterials (ESVB) from Friday, May 10th to Monday, May 13th at the Strasbourg Hilton in...
Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
May 3, 2013 1:00 pm | by PR Newswire | News | CommentsHUDSON, N.H., May 3, 2013 /PRNewswire/ -- Atrium Medical Corporation, a business unit of MAQUET Cardiovascular, today announced the 1-year results of the INFUSE-AMI (Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. Dr. Gregg Stone, the...
Researchers Determine Where Best to Place Defibrillators
May 3, 2013 9:55 am | by University of Toronto Faculty of Applied Science & Engineering | News | CommentsPrompt use of an automated external defibrillator, or AED, can greatly increase the survival rates of people who suffer a cardiac arrest. And MIE Professor Tim Chan, working with Dr. Laurie Morrison at St. Michael's Hospital, has developed a formula to determine where best to place these costly but life-saving devices.
